CN116726123A - Traditional Chinese medicine for treating optic neuritis and preparation method thereof - Google Patents
Traditional Chinese medicine for treating optic neuritis and preparation method thereof Download PDFInfo
- Publication number
- CN116726123A CN116726123A CN202310411417.6A CN202310411417A CN116726123A CN 116726123 A CN116726123 A CN 116726123A CN 202310411417 A CN202310411417 A CN 202310411417A CN 116726123 A CN116726123 A CN 116726123A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- optic neuritis
- treating
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 97
- 208000003435 Optic Neuritis Diseases 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 63
- 238000000926 separation method Methods 0.000 claims abstract description 46
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 24
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 24
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 24
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 24
- 229960004853 betadex Drugs 0.000 claims abstract description 24
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 21
- 239000000341 volatile oil Substances 0.000 claims abstract description 20
- 241000202726 Bupleurum Species 0.000 claims abstract description 19
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 19
- 235000006533 astragalus Nutrition 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- 241001061264 Astragalus Species 0.000 claims abstract description 15
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 15
- 210000004233 talus Anatomy 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000004821 distillation Methods 0.000 claims abstract description 10
- 238000004140 cleaning Methods 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000010298 pulverizing process Methods 0.000 claims abstract description 7
- 238000001694 spray drying Methods 0.000 claims abstract description 7
- 229940107666 astragalus root Drugs 0.000 claims abstract description 4
- 241001106477 Paeoniaceae Species 0.000 claims description 17
- 241000125175 Angelica Species 0.000 claims description 14
- 238000003825 pressing Methods 0.000 claims description 11
- 244000164480 Curcuma aromatica Species 0.000 abstract description 5
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 239000007921 spray Substances 0.000 abstract 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 35
- 210000004185 liver Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000382455 Angelica sinensis Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000045403 Astragalus propinquus Species 0.000 description 4
- 235000003398 Curcuma aromatica Nutrition 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 241000243684 Lumbricus Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D29/00—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor
- B01D29/01—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor with flat filtering elements
- B01D29/03—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor with flat filtering elements self-supporting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D29/00—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor
- B01D29/76—Handling the filter cake in the filter for purposes other than for regenerating
- B01D29/80—Handling the filter cake in the filter for purposes other than for regenerating for drying
- B01D29/82—Handling the filter cake in the filter for purposes other than for regenerating for drying by compression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating optic neuritis and a preparation method thereof, wherein the preparation method of the traditional Chinese medicine for treating optic neuritis comprises the following steps: preparing astragalus root, earthworm, bupleurum root, chinese angelica root, curcuma root and red peony root, cleaning and drying for standby; adding 10-15 times of water into the whole bupleurum, angelica and radix curcumae, extracting volatile oil by adopting a distillation method, and carrying out liquid medicine separation on residues by adopting a liquid medicine separation device to obtain medicine residues and liquid medicine; clathrating the volatile oil with beta-cyclodextrin, drying at low temperature, and pulverizing to obtain beta-cyclodextrin clathrate; adding the whole parts of astragalus, red paeony root and earthworm into the residues, adding water for decoction, filtering out decoction, mixing the decoction with the liquid medicine, and concentrating to obtain concentrated solution; spray drying the concentrated solution to obtain spray dry powder, and mixing the spray dry powder with the beta-cyclodextrin inclusion compound to prepare the traditional Chinese medicine for treating the optic neuritis.
Description
Technical Field
The application relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating optic neuritis and a preparation method thereof.
Background
Optic neuritis refers to a series of symptoms and signs caused by inflammatory reactive lesions of optic nerves, such as vision decline, visual field abnormality, optic disc edema and the like, and is one of the frequently-occurring diseases of young and young, clinical difficult diseases, although not an extremely serious disease, but if not treated in time, blindness can have serious influence on physical and mental health and daily life work of young and young patients.
At present, the treatment of the optic neuritis mainly adopts western medicine means and mainly comprises hormone medicine treatment and immunosuppressant treatment, but the recurrence rate and low efficiency after the treatment and the toxic and side effects of long-term application of hormone medicine and immunosuppressant medicine often cause patients to be hard to adhere to the treatment.
Disclosure of Invention
The application aims to provide a traditional Chinese medicine for treating optic neuritis and a preparation method thereof, which can have good curative effect on optic neuritis.
In order to achieve the above object, in a first aspect, the present application provides a method for preparing a traditional Chinese medicine for treating optic neuritis, comprising:
preparing 10-34 parts of astragalus, 3-10 parts of earthworm, 8-20 parts of bupleurum, 3-15 parts of angelica, 5-10 parts of radix curcumae and 4-20 parts of red paeony root by weight, cleaning and drying for later use;
adding 10-15 times of water into the whole bupleurum, angelica and radix curcumae, extracting volatile oil by adopting a distillation method, and carrying out liquid medicine separation on residues by adopting a liquid medicine separation device to obtain medicine residues and liquid medicine;
clathrating the volatile oil with beta-cyclodextrin, drying at low temperature, and pulverizing to obtain beta-cyclodextrin clathrate;
adding the whole parts of astragalus, red paeony root and earthworm into the dregs, adding water for decoction, filtering out decoction, mixing the decoction with the liquid medicine, and concentrating to obtain concentrated solution;
and (3) spray drying the concentrated solution to obtain spray-dried powder, and mixing the spray-dried powder with the beta-cyclodextrin inclusion compound to obtain the traditional Chinese medicine for treating the optic neuritis.
Wherein the relative density of the concentrated solution is 1.25-1.35.
Wherein the dosage of the beta-cyclodextrin is 3-6 times of the volatile oil quantity.
The liquid medicine separating device comprises a separating box, a lifting assembly, a box cover, a filter screen and a liquid outlet pipe; the lifting component is arranged at the side edge of the separation box; the box cover is arranged at the side edge of the lifting assembly; the filter screen is fixedly connected with the separation box and is positioned in the separation box; the liquid outlet pipe is fixedly connected and communicated with the separation box and is positioned at the side edge of the separation box.
Wherein, the liquid medicine separating device also comprises a first cylinder, a connecting rod and a pressing plate; the first cylinder is fixedly connected with the box cover and is positioned at the top of the box cover; the connecting rod is fixedly connected with the first cylinder output rod and is positioned at the bottom of the first cylinder; the pressing plate is fixedly connected with the connecting rod and is positioned at the bottom of the connecting rod.
Wherein the liquid medicine separating device further comprises a control valve; the control valve is fixedly connected with the liquid outlet pipe and is positioned at the side edge of the liquid outlet pipe.
In a second aspect, the application also provides a traditional Chinese medicine for treating optic neuritis, which comprises the following components in parts by weight: 10-34 parts of astragalus root, 3-10 parts of earthworm, 8-20 parts of bupleurum, 3-15 parts of angelica, 5-10 parts of radix curcumae and 4-20 parts of red paeony root.
The application relates to a traditional Chinese medicine for treating optic neuritis and a preparation method thereof, which adopts astragalus, earthworm, bupleurum, angelica, radix curcumae and red paeony root as raw materials, and the bupleurum is longer than the qi movement of liver, stomach, gall and triple energizer, and mainly treats liver depression and qi stagnation syndrome, soothes liver depression, qi circulation and pain relief, and enables qi movement to be smooth, thus being a monarch drug; astragalus mongholicus is used for reinforcing primordial qi of spleen and stomach, so that qi is vigorous, blood is circulated, blood stasis is removed, and collaterals are dredged; radix paeoniae rubra, radix angelicae sinensis, and radix angelicae sinensis are used as ministerial drugs, capable of promoting blood circulation, and tonifying blood, and removing blood stasis without damaging blood; radix Curcumae has effects of activating qi-flowing, resolving stagnation, cooling blood, removing blood stasis, and regulating qi movement; lumbricus is used as adjuvant drug for dredging meridian passage; the components are compatible, have the effects of soothing liver and relieving depression, tonifying qi and activating blood, have obvious and reliable curative effects on optic neuritis, especially optic neuritis with the symptoms of depression and qi stagnation, have short treatment course, take effect quickly, are safe and have no toxic or side effect, can achieve the aim of treating both symptoms and root causes, and are difficult to relapse after treatment.
Drawings
In order to more clearly illustrate the embodiments of the application or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, it being obvious that the drawings in the following description are only some embodiments of the application, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
Fig. 1 is a flowchart of a preparation method of a traditional Chinese medicine for treating optic neuritis.
Fig. 2 is a schematic structural view of the chemical liquid separation device of the present application.
The device comprises a 1-separation box, a 2-lifting assembly, a 3-box cover, a 4-filter screen, a 5-liquid outlet pipe, a 6-first cylinder, a 7-connecting rod, an 8-pressing plate, a 9-control valve, a 21-support, a 22-second cylinder and a 23-connecting plate.
Detailed Description
Embodiments of the present application are described in detail below, examples of which are illustrated in the accompanying drawings, wherein like or similar reference numerals refer to like or similar elements or elements having like or similar functions throughout. The embodiments described below by referring to the drawings are illustrative and intended to explain the present application and should not be construed as limiting the application.
Referring to fig. 1 to 2, in a first aspect, the present application provides a method for preparing a traditional Chinese medicine for treating optic neuritis, which includes:
s1, preparing 10-34 parts of astragalus, 3-10 parts of earthworm, 8-20 parts of radix bupleuri, 3-15 parts of angelica, 5-10 parts of radix curcumae and 4-20 parts of red paeony root according to parts by weight, cleaning and drying for later use;
s2, adding 10-15 times of water into the whole bupleurum, the angelica and the curcuma aromatica, extracting volatile oil by adopting a distillation method, and carrying out liquid medicine separation on residues by adopting a liquid medicine separation device to obtain medicine residues and liquid medicine;
s3, clathrating the volatile oil with beta-cyclodextrin, drying at low temperature, and pulverizing to obtain beta-cyclodextrin clathrate;
the dosage of the beta-cyclodextrin is 3-6 times of the volatile oil quantity.
S4, adding the whole parts of astragalus, red paeony root and earthworm into the dregs, adding water for decoction, filtering out decoction, mixing the decoction with the liquid medicine, and concentrating to obtain concentrated solution;
the relative density of the concentrated solution is 1.25-1.35.
S5, spray drying the concentrated solution to obtain spray-dried powder, and mixing the spray-dried powder with the beta-cyclodextrin inclusion compound to obtain the traditional Chinese medicine for treating the optic neuritis.
The traditional Chinese medicine used in the application has the following properties:
bupleurum root: sex taste: pungent, bitter and slightly cold; enter liver, gall bladder and lung meridian; function and main indications: liver soothing, qi stagnation relieving, blood circulation promoting, pain relieving, heat dispelling, yang qi lifting, and can be used for treating liver qi stagnation, blood deficiency, common cold, fever, cold and heat, chest pain, hypochondrium pain, etc.
Radix astragali: sex taste: sweet and slightly warm; the Chinese medicinal composition enters lung, spleen, liver and kidney meridians; function and main indications: the Chinese medicinal composition has effects of promoting vital essence generation, nourishing blood, promoting circulation of qi, relieving arthralgia, invigorating qi, invigorating yang, consolidating superficial resistance, arresting sweating, inducing diuresis, relieving edema, removing toxic substances, promoting pus discharge, healing sore, promoting granulation, and can be used for treating qi deficiency, debilitation, sinking of middle-jiao, spontaneous perspiration due to exterior deficiency, qi deficiency edema, internal heat diabetes, blood deficiency sallow complexion, hemiplegia, arthralgia, numbness, carbuncle, difficult ulcer, chronic ulcer, etc.
Chinese angelica root: sex taste: sweet, pungent and warm, enter liver, heart and spleen meridians; function and main indications: blood replenishing, blood activating, menstruation regulating, pain relieving, intestine moistening, and constipation relieving effects, and can be used for treating blood deficiency, sallow complexion, giddiness, palpitation, asthenia cold, abdominal pain, rheumatalgia, traumatic injury, etc.
Radix Curcumae: sex taste: pungent, bitter and cold; enter liver, heart and lung meridians; function and main indications: promoting blood circulation, relieving pain, activating qi-flowing, resolving stagnation, clearing heart fire, cooling blood, promoting bile flow, and relieving jaundice, and can be used for treating chest and hypochondrium pain, chest pain, fever unconsciousness, epilepsia, hemorrhage due to blood heat, jaundice, red urine, etc.
Radix paeoniae rubra: sex taste: bitter and slightly cold; enter liver meridian; function and main indications: clearing heat and cooling blood, removing blood stasis and relieving pain, and can be used for treating liver depression and hypochondriac pain, heat entering nutrient blood, toxic heat and spot, hematemesis and epistaxis, conjunctival congestion and swelling pain, abdominal pain, traumatic injury, etc.
Earthworm: sex taste: salty and cold; enter liver, spleen and bladder meridians; function and main indications: clearing heat and arresting convulsion, dredging collaterals, relieving asthma, promoting urination, and can be used for treating hyperpyrexia and unconsciousness, arthralgia, limb numbness, hemiplegia, lung heat asthma and cough, etc.
In the preparation method of the traditional Chinese medicine for treating the optic neuritis, bupleurum root is longer than qi movement of liver, stomach, gall and triple energizer, and mainly treats liver depression and qi stagnation syndrome, soothes liver and qi stagnation, and moves qi to relieve pain, so that qi movement is smooth and is a monarch drug; astragalus mongholicus is used for reinforcing primordial qi of spleen and stomach, so that qi is vigorous, blood is circulated, blood stasis is removed, and collaterals are dredged; radix paeoniae rubra, radix angelicae sinensis, and radix angelicae sinensis are used as ministerial drugs, capable of promoting blood circulation, and tonifying blood, and removing blood stasis without damaging blood; radix Curcumae has effects of activating qi-flowing, resolving stagnation, cooling blood, removing blood stasis, and regulating qi movement; lumbricus is used as adjuvant drug for dredging meridian passage.
For a better understanding of the present application, several specific examples are set forth below.
Example 1:
s1, preparing 10 parts of astragalus, 3 parts of earthworm, 8 parts of radix bupleuri, 3 parts of Chinese angelica, 5 parts of radix curcumae and 4 parts of red paeony root by weight, cleaning and drying for later use;
s2, adding 10-15 times of water into the whole bupleurum, the angelica and the curcuma aromatica, extracting volatile oil by adopting a distillation method, and carrying out liquid medicine separation on residues by adopting a liquid medicine separation device to obtain medicine residues and liquid medicine;
s3, clathrating the volatile oil with beta-cyclodextrin, drying at low temperature, and pulverizing to obtain beta-cyclodextrin clathrate;
s4, adding the whole parts of astragalus, red paeony root and earthworm into the dregs, adding water for decoction, filtering out decoction, mixing the decoction with the liquid medicine, and concentrating to obtain concentrated solution;
s5, spray drying the concentrated solution to obtain spray-dried powder, and mixing the spray-dried powder with the beta-cyclodextrin inclusion compound to obtain the traditional Chinese medicine for treating the optic neuritis.
Example 2:
s1, preparing 15 parts of astragalus, 5 parts of earthworm, 8 parts of radix bupleuri, 3 parts of Chinese angelica, 5 parts of radix curcumae and 4 parts of red paeony root by weight, cleaning and drying for later use;
s2, adding 10-15 times of water into the whole bupleurum, the angelica and the curcuma aromatica, extracting volatile oil by adopting a distillation method, and carrying out liquid medicine separation on residues by adopting a liquid medicine separation device to obtain medicine residues and liquid medicine;
s3, clathrating the volatile oil with beta-cyclodextrin, drying at low temperature, and pulverizing to obtain beta-cyclodextrin clathrate;
s4, adding the whole parts of astragalus, red paeony root and earthworm into the dregs, adding water for decoction, filtering out decoction, mixing the decoction with the liquid medicine, and concentrating to obtain concentrated solution;
s5, spray drying the concentrated solution to obtain spray-dried powder, and mixing the spray-dried powder with the beta-cyclodextrin inclusion compound to obtain the traditional Chinese medicine for treating the optic neuritis.
Example 3:
s1, preparing 20 parts of astragalus, 8 parts of earthworm, 15 parts of radix bupleuri, 8 parts of Chinese angelica, 8 parts of radix curcumae and 15 parts of red paeony root according to parts by weight, cleaning and drying for later use;
s2, adding 10-15 times of water into the whole bupleurum, the angelica and the curcuma aromatica, extracting volatile oil by adopting a distillation method, and carrying out liquid medicine separation on residues by adopting a liquid medicine separation device to obtain medicine residues and liquid medicine;
s3, clathrating the volatile oil with beta-cyclodextrin, drying at low temperature, and pulverizing to obtain beta-cyclodextrin clathrate;
s4, adding the whole parts of astragalus, red paeony root and earthworm into the dregs, adding water for decoction, filtering out decoction, mixing the decoction with the liquid medicine, and concentrating to obtain concentrated solution;
s5, spray drying the concentrated solution to obtain spray-dried powder, and mixing the spray-dried powder with the beta-cyclodextrin inclusion compound to obtain the traditional Chinese medicine for treating the optic neuritis.
The preparation method of the traditional Chinese medicine for treating the optic neuritis adopts astragalus, earthworm, bupleurum, angelica, radix curcumae and red paeony root as raw materials, is suitable for compatibility of the components, has the effects of soothing liver and relieving depression, tonifying qi and activating blood, has obvious and reliable curative effects on the optic neuritis, especially the optic neuritis with the symptom of depression and depression, and has the advantages of short treatment course, quick response, safety, no toxic or side effect, and capability of achieving the aim of treating both symptoms and root causes, and is difficult to relapse after treatment.
Further, the liquid medicine separating device comprises a separating box 1, a lifting assembly 2, a box cover 3, a filter screen 4 and a liquid outlet pipe 5; the lifting assembly 2 is arranged at the side edge of the separation box 1; the box cover 3 is arranged at the side edge of the lifting assembly 2; the filter screen 4 is fixedly connected with the separation box 1 and is positioned in the separation box 1; the liquid outlet pipe 5 is fixedly connected and communicated with the separation box 1 and is positioned at the side edge of the separation box 1.
In this embodiment, the lifting assembly 2 is controlled to drive the tank cover 3 to move upwards, then residues remained after the volatile oil is extracted by distillation in the step S2 are added into the separation tank 1, the residues fall onto the filter screen 4, the liquid medicine passes through the filter screen 4 to enter the bottom of the separation tank 1, the liquid medicine is discharged from the separation tank 1 through the liquid outlet pipe 5, and the residues are remained on the filter screen 4, so as to obtain separated residues and liquid medicine.
Further, the liquid medicine separating device further comprises a first cylinder 6, a connecting rod 7 and a pressing plate 8; the first air cylinder 6 is fixedly connected with the box cover 3 and is positioned at the top of the box cover 3; the connecting rod 7 is fixedly connected with the output rod of the first air cylinder 6 and is positioned at the bottom of the first air cylinder 6; the pressing plate 8 is fixedly connected with the connecting rod 7 and is positioned at the bottom of the connecting rod 7.
In this embodiment, the lifting assembly 2 is controlled to drive the box cover 3 to move upwards, then residues left after volatile oil is extracted by a distillation method in the step S2 are added into the separation box 1, the residues fall onto the filter screen 4, the lifting assembly 2 is controlled to drive the box cover 3 to move downwards to the top of the separation box 1, the first cylinder 6 is used to drive the connecting rod 7 and the pressing plate 8 to move downwards, the pressing plate 8 applies pressure to the residues on the filter screen 4, so that liquid medicine passes through the filter screen 4 to enter the bottom of the separation box 1, the liquid medicine is discharged from the separation box 1 through the liquid outlet pipe 5, and the residues remain on the filter screen 4, thereby obtaining separated residues and liquid medicine, and improving the separation efficiency.
Further, the liquid medicine separating device further comprises a control valve 9; the control valve 9 is fixedly connected with the liquid outlet pipe 5 and is positioned at the side edge of the liquid outlet pipe 5.
In the present embodiment, the communication and closing of the liquid outlet pipe 5 can be controlled by the control valve 9.
Further, the lifting assembly 2 comprises a support 21, a second cylinder 22 and a connecting plate 23; the support 21 is fixedly connected with the separation box 1 and is positioned at the side edge of the separation box 1; the second air cylinder 22 is fixedly connected with the support 21 and is positioned at the top of the support 21; the connecting plate 23 is fixedly connected with the output rod of the second cylinder 22, fixedly connected with the box cover 3 and positioned at the top of the second cylinder 22.
In this embodiment, the support 21 is configured to support the second cylinder 22, control the second cylinder 22 to drive the connecting plate 23 and the case cover 3 to move upwards, then add the residue left after the volatile oil is extracted by distillation in the step S2 into the separation case 1, drop the residue onto the filter screen 4, control the second cylinder 22 to drive the case cover 3 to move downwards to the top of the separation case 1, drive the connecting rod 7 and the pressing plate 8 to move downwards through the first cylinder 6, and press the residue on the filter screen 4 by the pressing plate 8, so that the liquid medicine passes through the filter screen 4 to enter the bottom of the separation case 1, is discharged from the separation case 1 through the liquid outlet pipe 5, and the residue remains on the filter screen 4, thereby obtaining separated residue and liquid medicine, and improving the separation efficiency.
In a second aspect, the application also provides a traditional Chinese medicine for treating optic neuritis, which comprises the following components in parts by weight: 10-34 parts of astragalus root, 3-10 parts of earthworm, 8-20 parts of bupleurum, 3-15 parts of angelica, 5-10 parts of radix curcumae and 4-20 parts of red paeony root.
The Chinese medicine for treating the optic neuritis provided by the application has the advantages that the bupleurum root is longer than the qi movement of liver, stomach, gall and triple energizer, and is mainly used for treating liver depression and qi stagnation, soothing liver, relieving depression, promoting qi circulation, relieving pain and enabling qi movement to be smooth, and is a monarch drug; astragalus mongholicus is used for reinforcing primordial qi of spleen and stomach, so that qi is vigorous, blood is circulated, blood stasis is removed, and collaterals are dredged; radix paeoniae rubra, radix angelicae sinensis, and radix angelicae sinensis are used as ministerial drugs, capable of promoting blood circulation, and tonifying blood, and removing blood stasis without damaging blood; radix Curcumae has effects of activating qi-flowing, resolving stagnation, cooling blood, removing blood stasis, and regulating qi movement; lumbricus is used as adjuvant drug for dredging meridian passage; the traditional Chinese medicine composition is prepared from astragalus membranaceus, earthworm, radix bupleuri, angelica sinensis, radix curcumae and radix paeoniae rubra, is suitable for compatibility of the components, has the effects of soothing liver and relieving depression, tonifying qi and activating blood, has obvious and reliable curative effects on optic neuritis, especially optic neuritis with the symptom of depression and depression, and is short in treatment course, quick in effect taking, safe, free of toxic and side effects, capable of achieving the aim of treating both symptoms and root causes, and difficult to recur after treatment.
The above disclosure is only a preferred embodiment of the present application, and it should be understood that the scope of the application is not limited thereto, and those skilled in the art will appreciate that all or part of the procedures described above can be performed according to the equivalent changes of the claims, and still fall within the scope of the present application.
Claims (7)
1. The preparation method of the traditional Chinese medicine for treating the optic neuritis is characterized by comprising the following steps:
preparing 10-34 parts of astragalus, 3-10 parts of earthworm, 8-20 parts of bupleurum, 3-15 parts of angelica, 5-10 parts of radix curcumae and 4-20 parts of red paeony root by weight, cleaning and drying for later use;
adding 10-15 times of water into the whole bupleurum, angelica and radix curcumae, extracting volatile oil by adopting a distillation method, and carrying out liquid medicine separation on residues by adopting a liquid medicine separation device to obtain medicine residues and liquid medicine;
clathrating the volatile oil with beta-cyclodextrin, drying at low temperature, and pulverizing to obtain beta-cyclodextrin clathrate;
adding the whole parts of astragalus, red paeony root and earthworm into the dregs, adding water for decoction, filtering out decoction, mixing the decoction with the liquid medicine, and concentrating to obtain concentrated solution;
and (3) spray drying the concentrated solution to obtain spray-dried powder, and mixing the spray-dried powder with the beta-cyclodextrin inclusion compound to obtain the traditional Chinese medicine for treating the optic neuritis.
2. The method for preparing the traditional Chinese medicine for treating the optic neuritis according to claim 1, which is characterized in that,
the relative density of the concentrated solution is 1.25-1.35.
3. The method for preparing the traditional Chinese medicine for treating the optic neuritis according to claim 1, which is characterized in that,
the dosage of the beta-cyclodextrin is 3-6 times of the volatile oil quantity.
4. The method for preparing the traditional Chinese medicine for treating the optic neuritis according to claim 1, which is characterized in that,
the liquid medicine separating device comprises a separating box, a lifting assembly, a box cover, a filter screen and a liquid outlet pipe; the lifting component is arranged at the side edge of the separation box; the box cover is arranged at the side edge of the lifting assembly; the filter screen is fixedly connected with the separation box and is positioned in the separation box; the liquid outlet pipe is fixedly connected and communicated with the separation box and is positioned at the side edge of the separation box.
5. The method for preparing a traditional Chinese medicine for treating optic neuritis according to claim 4, wherein,
the liquid medicine separating device further comprises a first cylinder, a connecting rod and a pressing plate; the first cylinder is fixedly connected with the box cover and is positioned at the top of the box cover; the connecting rod is fixedly connected with the first cylinder output rod and is positioned at the bottom of the first cylinder; the pressing plate is fixedly connected with the connecting rod and is positioned at the bottom of the connecting rod.
6. The method for preparing a traditional Chinese medicine for treating optic neuritis according to claim 5, wherein,
the liquid medicine separating device further comprises a control valve; the control valve is fixedly connected with the liquid outlet pipe and is positioned at the side edge of the liquid outlet pipe.
7. A traditional Chinese medicine for treating optic neuritis, which is prepared by adopting the preparation method of the traditional Chinese medicine for treating optic neuritis according to any one of claims 1-6, and is characterized by comprising the following components in parts by weight: 10-34 parts of astragalus root, 3-10 parts of earthworm, 8-20 parts of bupleurum, 3-15 parts of angelica, 5-10 parts of radix curcumae and 4-20 parts of red paeony root.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310411417.6A CN116726123A (en) | 2023-04-17 | 2023-04-17 | Traditional Chinese medicine for treating optic neuritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310411417.6A CN116726123A (en) | 2023-04-17 | 2023-04-17 | Traditional Chinese medicine for treating optic neuritis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116726123A true CN116726123A (en) | 2023-09-12 |
Family
ID=87914027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310411417.6A Pending CN116726123A (en) | 2023-04-17 | 2023-04-17 | Traditional Chinese medicine for treating optic neuritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116726123A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069364A (en) * | 2013-03-26 | 2014-10-01 | 李金保 | Traditional Chinese medicine for treating optic atrophy |
| CN109663100A (en) * | 2019-01-29 | 2019-04-23 | 山西中医药大学 | A kind of Chinese medicine composition and its preparation method and application for treating optic neuritis |
| CN213383131U (en) * | 2020-09-11 | 2021-06-08 | 江西亿圆生物药业有限公司 | Medicine residue separator is used in chinese herbal medicine production and processing |
| CN214680539U (en) * | 2021-02-23 | 2021-11-12 | 天津中科博蕴生物技术有限公司 | Traditional chinese medicine draws liquid medicine dregs of a decoction splitter |
-
2023
- 2023-04-17 CN CN202310411417.6A patent/CN116726123A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069364A (en) * | 2013-03-26 | 2014-10-01 | 李金保 | Traditional Chinese medicine for treating optic atrophy |
| CN109663100A (en) * | 2019-01-29 | 2019-04-23 | 山西中医药大学 | A kind of Chinese medicine composition and its preparation method and application for treating optic neuritis |
| CN213383131U (en) * | 2020-09-11 | 2021-06-08 | 江西亿圆生物药业有限公司 | Medicine residue separator is used in chinese herbal medicine production and processing |
| CN214680539U (en) * | 2021-02-23 | 2021-11-12 | 天津中科博蕴生物技术有限公司 | Traditional chinese medicine draws liquid medicine dregs of a decoction splitter |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101279077B (en) | Preparation of Chinese medicine lotion for curing closed fracture | |
| CN107789484B (en) | Traditional Chinese medicine composition for treating irregular menstruation and preparation method thereof | |
| CN101897821A (en) | Granular preparation for promoting blood circulation, dredging collaterals and relieving pain and preparation method as well as quality control method thereof | |
| CN105878927A (en) | Method for preparing medical composition capable of treating haemorrhoid | |
| CN104225319A (en) | Traditional Chinese preparation for treating acute renal failure | |
| CN1246028C (en) | Medicine for treating various kinds of fistulas and pilesand anal fistula | |
| CN103977106B (en) | A kind of Chinese medicine preparation for the treatment of nephrotic syndrome and preparation method thereof | |
| CN116726123A (en) | Traditional Chinese medicine for treating optic neuritis and preparation method thereof | |
| CN1712047B (en) | Chinese medicinal composition for treating adenomyosis uteri | |
| CN104189764A (en) | Traditional Chinese medicinal preparation for treating intervention postoperative fever | |
| CN1176794A (en) | Medicine for treating masculine sterility | |
| CN103041263B (en) | Traditional Chinese medicine rectal administration suppository for curing chronic prostatitis and preparing method thereof | |
| CN102166311B (en) | Preparation method of Chinese medicine for treating spleen-deficiency sthenic liver-energy hyperthyroidism | |
| CN105770487A (en) | Traditional Chinese medicine composition for treating cerebral infarction and cerebral hemorrhage sequelae and preparation method thereof | |
| CN104800764A (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method | |
| CN101297907A (en) | Preparation of Chinese medicine for curing sthenia fire type dentalgia | |
| CN104689252A (en) | Traditional Chinese preparation for treating Wegener granulomatosis and preparation method thereof | |
| CN104338052A (en) | Formula of traditional Chinese medicine for treating cerebral thrombosis | |
| CN104083548A (en) | Traditional Chinese medicinal composition for treating ovarian cyst and preparation method thereof | |
| CN108434380A (en) | It is a kind of to treat hydrocephalic Chinese medicine composition and preparation method thereof | |
| CN108543038B (en) | Traditional Chinese medicine composition for removing blood stasis and stopping bleeding as well as preparation method and application thereof | |
| CN105456447A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition with function of promoting blood circulation to remove stasis and preparation method thereof | |
| CN105396034A (en) | Medicine for amebic dysentery | |
| CN105770552A (en) | Chinese herba preparation containing folium artemisiae argyi and used for treating prostatitis and preparing method thereof | |
| CN104984307A (en) | Chinese herb preparation treating salpingemphraxis and preparing method of Chinese herb preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230907 Address after: 314500 Room 405, Floor 4, Building 3, No. 550, Tongde Road, wutong Street, Tongxiang City, Jiaxing City, Zhejiang Province Applicant after: Zhejiang tongben Technology Co.,Ltd. Address before: Room 409-003, Building 8, No. 133 Development Avenue, Tongxiang Economic Development Zone, Tongxiang City, Jiaxing City, Zhejiang Province, 314500 Applicant before: Jiaxing Liangmou Medical Technology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |